321 related articles for article (PubMed ID: 32237070)
1. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing medication-taking behaviour with adjuvant endocrine therapy in women with breast cancer: A qualitative systematic review.
Xu H; Zhang XJ; Wang DQ; Xu L; Wang AP
J Adv Nurs; 2020 Feb; 76(2):445-458. PubMed ID: 31657028
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
Quinn EM; Fleming C; O'Sullivan MJ
Ir J Med Sci; 2016 May; 185(2):383-92. PubMed ID: 25971465
[TBL] [Abstract][Full Text] [Related]
6. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
7. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
8. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
11. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
12. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
Bright EE; Petrie KJ; Partridge AH; Stanton AL
Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
[TBL] [Abstract][Full Text] [Related]
13. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
Lundgren C; Lindman H; Rolander B; Ekholm M
Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
[TBL] [Abstract][Full Text] [Related]
14. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
15. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
16. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
17. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
18. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
19. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]